Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 3
1(14.3%)
7Total
Phase 1(6)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07223944Phase 3Recruiting

A Gaucher Disease Gene Therapy Trial With FLT201

Role: lead

NCT05324943Phase 1Completed

A Gene Therapy Study in Patients With Gaucher Disease Type 1

Role: lead

NCT06545136Phase 1Active Not Recruiting

Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

Role: lead

NCT04455230Phase 1Completed

A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190

Role: lead

NCT05164471Phase 1Terminated

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Role: lead

NCT03641703Phase 1Terminated

A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy

Role: lead

NCT04040049Phase 1Terminated

A Fabry Disease Gene Therapy Study

Role: lead

NCT04272554Completed

AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)

Role: lead

All 8 trials loaded